Effect of Age on the Median Effective Dose(ED50) for Motor Block With Intrathecal Ropivacaine
Spinal
2 other identifiers
observational
120
1 country
1
Brief Summary
The primary aim of this study was to determine the median effective dose (ED50) for motor block of intrathecally-administered ropivacaine in adults (20-80 years), and to assess the effect of age on ED50 required for motor block.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 24, 2014
CompletedFirst Posted
Study publicly available on registry
April 3, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedOctober 27, 2015
October 1, 2015
1.2 years
March 24, 2014
October 23, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the dose of intrathecal ropivacaine
at 5-min after administered ropivacaine
Study Arms (1)
age
subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
Interventions
subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
Eligibility Criteria
Adult patients who were undergoing transurethral, urological or lower limb surgery, primarily under the spinal anesthesia
You may qualify if:
- Adult patients who were undergoing transurethral, urological or lower limb surgery, primarily under the spinal anesthesia
You may not qualify if:
- Patients with diabetes, obesity, neuromuscular diseases, bleeding diathesis, hypersensitivity to amide local anesthetics, lumbar vertebrae abnormality, chronic back pain, or who were pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
China Three Gorges University
Yichang, Hubei, 443003, China
Related Publications (2)
Lee YY, Ngan Kee WD, Fong SY, Liu JT, Gin T. The median effective dose of bupivacaine, levobupivacaine, and ropivacaine after intrathecal injection in lower limb surgery. Anesth Analg. 2009 Oct;109(4):1331-4. doi: 10.1213/ane.0b013e3181b1912b.
PMID: 19762766BACKGROUNDGupta R, Bogra J, Singh PK, Saxena S, Chandra G, Kushwaha JK. Comparative study of intrathecal hyperbaric versus isobaric ropivacaine: A randomized control trial. Saudi J Anaesth. 2013 Jul;7(3):249-53. doi: 10.4103/1658-354X.115326.
PMID: 24015125BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
jun yang, PhD
China Three Gorges University
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- the First College of Clinical Medical Science, China Three Gorges University (China)
Study Record Dates
First Submitted
March 24, 2014
First Posted
April 3, 2014
Study Start
January 1, 2014
Primary Completion
March 1, 2015
Study Completion
June 1, 2015
Last Updated
October 27, 2015
Record last verified: 2015-10